Lyka Labs Ltd

Lyka Labs Ltd

₹ 109 -1.27%
27 May - close price
About

Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]

Key Points

Business Overview:[1]
LLL is a WHO-GMP certified and ISO 9001- certified manufacturer of Pharmaceutical Formulations & Active Pharmaceutical Ingredients across various therapeutic segments, including Lyophilized injections, topical formulations of cream, ointment, foams, gels & lotions.

  • Market Cap 359 Cr.
  • Current Price 109
  • High / Low 144 / 92.6
  • Stock P/E
  • Book Value 30.0
  • Dividend Yield 0.00 %
  • ROCE 2.69 %
  • ROE -2.92 %
  • Face Value 10.0

Pros

  • Company has reduced debt.
  • Company is expected to give good quarter
  • Promoter holding has increased by 3.29% over last quarter.

Cons

  • Company has low interest coverage ratio.
  • Debtor days have increased from 68.4 to 88.3 days.
  • Working capital days have increased from 47.9 days to 77.8 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
17.82 43.47 65.02 28.18 27.68 21.88 22.13 17.13 19.46 21.24 26.76 31.42 26.98
12.35 13.66 20.82 16.25 16.12 15.96 17.40 14.91 16.73 18.69 22.82 25.56 24.76
Operating Profit 5.47 29.81 44.20 11.93 11.56 5.92 4.73 2.22 2.73 2.55 3.94 5.86 2.22
OPM % 30.70% 68.58% 67.98% 42.33% 41.76% 27.06% 21.37% 12.96% 14.03% 12.01% 14.72% 18.65% 8.23%
-0.85 0.53 -1.18 0.85 -2.14 0.68 0.90 -5.79 0.47 0.43 0.25 0.52 0.38
Interest 6.31 6.89 5.53 4.60 2.91 2.80 2.91 3.04 2.81 1.33 1.17 1.26 1.04
Depreciation 1.95 2.05 2.09 2.12 9.13 3.41 3.46 3.33 3.32 3.34 3.46 2.72 2.77
Profit before tax -3.64 21.40 35.40 6.06 -2.62 0.39 -0.74 -9.94 -2.93 -1.69 -0.44 2.40 -1.21
Tax % 106.59% 8.18% 15.79% 6.27% -481.30% 15.38% 45.95% -2.82% -2.39% -2.37% 34.09% 43.33% -33.06%
0.23 19.65 29.81 5.68 -15.24 0.33 -0.40 -10.21 -3.01 -1.72 -0.29 1.36 -1.62
EPS in Rs 0.08 6.85 10.39 1.98 -5.31 0.12 -0.14 -3.56 -0.98 -0.52 -0.09 0.41 -0.49
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
95 87 90 57 78 42 41 41 62 164 81 106
82 88 72 49 56 42 40 44 48 67 65 92
Operating Profit 13 -2 18 8 22 -1 1 -3 14 98 16 15
OPM % 13% -2% 20% 14% 28% -1% 2% -8% 23% 59% 19% 14%
4 24 5 11 -0 3 2 -25 1 -2 -4 2
Interest 16 24 18 11 17 8 6 19 26 20 12 5
Depreciation 3 5 4 3 6 6 4 8 8 15 14 12
Profit before tax -3 -7 1 5 -1 -11 -7 -55 -18 60 -13 -1
Tax % 0% 0% 0% 0% 66% 3% 124% -0% 21% 34% -1% -143%
-3 -7 1 5 -0 -11 2 -55 -14 40 -13 -2
EPS in Rs -1.30 -3.37 0.63 2.19 -0.09 -3.85 0.61 -19.31 -5.04 13.91 -4.33 -0.69
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 21%
3 Years: 20%
TTM: 32%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 22%
TTM: 63%
Stock Price CAGR
10 Years: 24%
5 Years: 33%
3 Years: 16%
1 Year: 16%
Return on Equity
10 Years: -6%
5 Years: -3%
3 Years: 22%
Last Year: -3%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 22 22 22 22 22 28 28 29 29 29 31 33
Reserves 45 40 38 43 52 68 70 -10 -24 16 28 66
Preference Capital 1 1 1 1 0 1 1 1 1 1 1
128 139 108 105 112 101 90 136 162 128 73 57
52 62 66 58 57 48 60 66 47 36 47 29
Total Liabilities 247 263 233 228 243 245 249 221 213 209 179 186
95 94 62 60 86 81 76 102 95 90 66 57
CWIP 15 22 27 30 24 26 30 26 24 18 16 22
Investments 20 63 63 63 62 62 62 32 32 32 32 32
116 84 82 75 70 75 80 61 61 68 65 75
Total Assets 247 263 233 228 243 245 249 221 213 209 179 186

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
14 55 29 8 20 7 18 -11 6 77 7 3
-10 -25 30 5 -5 -3 -3 0 0 -4 7 -9
-1 -29 -63 -13 -15 -4 -16 20 -8 -63 -20 3
Net Cash Flow 3 2 -3 0 -0 -1 -0 8 -2 9 -7 -3

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 229 107 116 169 113 265 263 59 58 39 78 88
Inventory Days 94 58 90 74 93 124 98 99 67 97 87 81
Days Payable 243 235 283 323 283 536 519 430 301 109 103 93
Cash Conversion Cycle 80 -70 -77 -80 -76 -147 -159 -272 -176 26 62 77
Working Capital Days 105 -153 -167 -196 -222 -456 -62 -201 -90 11 55 78
ROCE % 7% -1% 9% 9% 10% -3% -0% -5% 5% 50% 4%

Shareholding Pattern

Numbers in percentages

1 Recently
Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Apr 2024
20.00% 20.04% 47.79% 47.80% 47.58% 47.58% 51.00% 54.58% 54.81% 54.81% 54.81% 58.11%
2.07% 1.13% 1.12% 0.76% 0.57% 0.37% 0.18% 0.17% 0.18% 0.17% 0.17% 0.16%
1.85% 0.47% 1.19% 3.99% 4.00% 4.00% 3.74% 0.41% 0.41% 0.62% 0.81% 0.75%
76.08% 78.36% 49.89% 47.45% 47.85% 48.05% 45.08% 44.84% 44.61% 44.41% 44.21% 40.98%
No. of Shareholders 20,67227,72026,22026,96928,43328,51526,82027,20226,65226,42225,71725,699

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents